UBS Maintains Buy on American Healthcare REIT, Lowers Price Target to $62
UBS analyst Michael Goldsmith maintains American Healthcare REIT (NYSE:AHR) with a Buy and lowers the price target from $63 to $62.
Stocks · News reference
This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated coverage on NHP (Outperform, $20), OIG (Buy, $13), ETRA (Overweight), AHR (Strong Buy, $62).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Overweight on American Healthcare REIT, Lowers Price Target to $60
Barclays analyst Richard Hightower maintains American Healthcare REIT (NYSE:AHR) with a Overweight and lowers the price target from $66 to $60.
Raymond James Initiates Coverage On American Healthcare REIT with Strong Buy Rating, Announces Price Target of $62
Raymond James analyst David Rodgers initiates coverage on American Healthcare REIT (NYSE:AHR) with a Strong Buy rating and announces Price Target of $62.
Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company
Cronos Group has completed its acquisition of CanAdelaar B.V., the largest cannabis company in the Netherlands' adult-use cannabis pilot program (Wietexperiment), for a base purchase price of €57.5 million plus contingent cash earnouts. The acquisition establishes Cronos as the market leader in Europe's largest adult-use cannabis market and enables the company to execute its borderless product strategy in the Netherlands with CanAdelaar's proven operational track record and leading market share.
8-K filing — Cronos Group Inc. (CRON)
Filed: 2026-10-15 AccNo: 0001656472-26-000061 Size: 301 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Zuanic & Associates Initiates Coverage On Cronos Group with Overweight Rating
Zuanic & Associates analyst Pablo Zuanic initiates coverage on Cronos Group (NASDAQ:CRON) with a Overweight rating.